Guided Therapeutics, Inc.

Guided Therapeutics, Inc.

OOTC:GTHP
0.11
USD
0.00
(0.00%)
-0.04EPS
22.20MMarket Cap

Total Valuation

USD

As of March 31, 2026, Guided Therapeutics, Inc. carries a market capitalization of 22.20M, placing it among publicly traded companies globally. Its enterprise value stands at 25.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap22.20M
Enterprise Value25.33M

Share Statistics

As of March 31, 2026, Guided Therapeutics, Inc. has 96.51M shares outstanding.

Shares Outstanding96.51M

Valuation Ratios

These figures are as of March 31, 2026. The price-to-sales ratio is 25.15, and the price-to-book ratio stands at -3.77.

PS Ratio25.15
PB Ratio-3.77
P/TBV Ratio-3.77
P/FCF Ratio-14.25
P/OCF Ratio-14.25

Enterprise Valuation

These figures are as of March 31, 2026. The EV/Sales ratio of 33.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 25.33M versus a market cap of 22.20M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales33.02

Financial Position

As of March 31, 2026, Guided Therapeutics, Inc. maintains a current ratio of 0.15, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -53.81, indicating conservative leverage, while an interest coverage ratio of -3.47 demonstrates limited ability to service its debt obligations.

Current Ratio0.15
Quick Ratio0.06
Debt / Equity-53.81
Debt / EBITDA-1.29
Interest Coverage-3.47

Financial Efficiency

USD

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -254.45, reflecting losses generated across the asset base. The company generates approximately 102,266.67 in revenue per employee across its workforce of 7.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.35 indicates how many times Guided Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-254.45
Revenue Per Employee102,266.67
Employee Count7.50
Inventory Turnover0.35

Stock Price Statistics

USD

As of the close on November 16, 2026, Guided Therapeutics, Inc.'s stock has declined approximately 31.25% over the past 52 weeks. The 50-day moving average sits at 0.18, while the 200-day moving average is 0.26.

52-Week Price Change-31.25%
50-Day Moving Average0.18
200-Day Moving Average0.26

Income Statement

USD

Over the twelve months ended March 31, 2026, Guided Therapeutics, Inc. generated 767,000.00 in revenue and converted that into -3.27M in net income, yielding earnings per share of -0.04. EBITDA reached -2.15M, while operating income came in at -2.26M.

Revenue767,000.00
Gross Profit572,000.00
Operating Income-2.26M
Pretax Income-3.27M
Net Income-3.27M
EBITDA-2.15M
EBIT-2.26M
Earnings Per Share (EPS)-0.04

Balance Sheet

USD

As of March 31, 2026, Guided Therapeutics, Inc. holds 369,000.00 in cash and equivalents against 2.79M in total debt, resulting in a net debt position of 1.73M. Total book value stands at -5.89M, with working capital of -5.05M providing operational flexibility.

Cash & Cash Equivalents369,000.00
Total Debt2.79M
Net Debt1.73M
Equity (Book Value)-5.89M
Book Value Per Share-0.06
Working Capital-5.05M

Cash Flow

USD

Guided Therapeutics, Inc. produced -1.35M in operating cash flow over the twelve months ended March 31, 2026. After subtracting - - in capital expenditures, free cash flow totaled -1.35M - equivalent to -0.02 per share.

Operating Cash Flow-1.35M
Free Cash Flow-1.35M
FCF Per Share-0.02

Margins

Over the twelve months ended March 31, 2026, Guided Therapeutics, Inc. posted a gross margin of 74.58, reflecting its pricing power and cost economics. The operating margin of -294.65 and net profit margin of -426.47 provide insight into operational efficiency.

Gross Margin74.58
Operating Margin-294.65
Pretax Margin-426.47
Profit Margin-426.47
EBITDA Margin-280.83

Dividends & Yields

These figures cover the twelve months ended March 31, 2026. The dividend payout ratio of 3.40 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -7.02: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.25, meaning Guided Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Payout Ratio3.40
Shareholder Yield-7.25
FCF Yield-7.02

Stock Splits

Guided Therapeutics, Inc.'s most recent stock split took place on March 29, 2019 with a 800:1 split ratio.

Last Split Date3/29/2019
Split Ratio800:1

Scores

As of March 31, 2026, Guided Therapeutics, Inc. has an Altman Z-Score of -143.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-143.95